Open Access

[64Cu]NOTA-pentixather enables high resolution PET imaging of CXCR4 expression in a preclinical lymphoma model

  • Andreas Poschenrieder1,
  • Margret Schottelius1Email author,
  • Theresa Osl1,
  • Markus Schwaiger2 and
  • Hans-Jürgen Wester1
EJNMMI Radiopharmacy and Chemistry20172:2

https://doi.org/10.1186/s41181-016-0020-6

Received: 11 November 2016

Accepted: 22 December 2016

Published: 19 January 2017

Abstract

Background

The chemokine receptor 4 (CXCR4) is an important molecular target for both visualization and therapy of tumors. The aim of the present study was the synthesis and preclinical evaluation of a 64Cu-labeled, CXCR4-targeting peptide for positron emission tomography (PET) imaging of CXCR4 expression in vivo.

Methods

For this purpose, 1,4,7-triazacyclononane,1-glutaric acid-4,7-acetic acid (NODAGA), or 1,4,7-triazacyclononane-triacetic acid (NOTA) was conjugated to the highly affine CXCR4-targeting pentixather scaffold. Affinities were determined using Jurkat T-lymphocytes in competitive binding assays employing [125I]FC131 as the radioligand. Internalization and efflux studies of [64Cu]NOTA-pentixather were performed in chem-1 cells, stably transfected with hCXCR4. The stability of the tracer was evaluated in vitro and in vivo. Small-animal PET and biodistribution studies at different time points were performed in Daudi lymphoma-bearing severe combined immunodeficiency (SCID) mice.

Results

[64Cu]NOTA-pentixather was rapidly radiolabeled at 60 °C with high radiochemical yields ≥90% and purities >99%. [64Cu]NOTA-pentixather offered the highest affinity of the evaluated peptides in this study (IC50 = 14.9 ± 2.1 nM), showed efficient CXCR4-targeting in vitro and was stable in blood and urine with high resistance to transchelation in ethylenediaminetetraacetic acid (EDTA) challenge studies. Due to the enhanced lipophilicity of [64Cu]NOTA-pentixather (logP = -1.2), biodistribution studies showed some nonspecific accumulation in the liver and intestines. However, tumor accumulation (13.1 ± 1.5% ID/g, 1.5 h p.i.) was CXCR4-specific and higher than in all other organs and resulted in high resolution delineation of Daudi tumors in PET/CT images in vivo.

Conclusions

[64Cu]NOTA-pentixather was fast and efficiently radiolabeled, showed effective CXCR4-targeting, high stability in vitro and in vivo and resulted in high resolution PET/CT images accompanied with a suitable biodistribution profile, making [64Cu]NOTA-pentixather a promising tracer for future application in humans.

Keywords

64CuCancerCXCR4GPCRNOTAPentapeptidePETRadiopharmaceuticalTheranosticTracer

Background

Physiologically, the chemokine receptor 4 (CXCR4) and its only endogenous ligand CXCL12 act through G-protein signaling which leads to chemotaxis, cell adhesion, survival, and proliferation (Kuil et al. 2012a; Hattermann & Mentlein 2013; Burger & Kipps 2006). In cancer, the CXCR4-CXCL12 axis is involved in tumor growth and progression, invasion and organ-specific metastasis, therapy resistance as well as recurrence (Chatterjee et al. 2014; Burger & Peled 2009; Domanska et al. 2013). Therefore, CXCR4 is an attractive molecular target, both for therapeutic interventions and for noninvasive quantification of CXCR4 expression, the latter providing important information on the stage and kinetics of the disease. In recent years, a variety of high-affinity CXCR4-targeted imaging probes have been developed for this application, with a focus on targeted peptides, including derivatives of T140 labeled with various radionuclides (George et al. 2014; Yan et al. 2015; Jacobson et al. 2010; Tamamura et al. 2003; Tamamura et al. 1998; Jacobson et al. 2012; Hanaoka et al. 2006), FC131 (Gourni et al. 2011; Demmer et al. 2011a; Demmer et al. 2011b; Tanaka et al. 2010; Poschenrieder et al. 2016a), and small molecules such as AMD3100 (plerixafor)-based derivatives, that have been labeled with 64Cu (Weiss et al. 2012; De Silva et al. 2011; Nimmagadda et al. 2010; Jacobson et al. 2009; Woodard et al. 2014), 18F (Oltmanns et al. 2011), 11C (Hartimath et al. 2014), and 68Ga (Poty et al. 2016). Summaries of CXCR4-targeting probes have recently been reported in excellent reviews (Kuil et al. 2012b; Debnath et al. 2013; Weiss & Jacobson 2013). Amongst CXCR4-targeted imaging agents, [68Ga]pentixafor (Gourni et al. 2011; Demmer et al. 2011a) holds a prominent position, because its excellent CXCR4-targeting properties and fast renal excretion allow for high contrast PET imaging of CXCR4 expression in humans. Combined with a favorable dosimetry (Herrmann et al. 2015) these properties have paved the way for first currently ongoing clinical studies (Philipp-Abbrederis et al. 2015; Wester et al. 2015; Lapa et al. 2016a; Lapa et al. 2016b; Vag et al. 2016; Herhaus et al. 2016).

Recently, a corresponding therapeutic analog with a slightly modified peptide backbone, [177Lu]pentixather, has been introduced, and in first-in-man studies in patients with multiple myeloma, CXCR4-targeted endoradiotherapy using [177Lu]pentixather produced promising metabolic responses (Schottelius et al. 2015; Herrmann et al. 2016). [177Lu]pentixather thus complements diagnostic imaging with [68Ga]pentixafor to a first CXCR4-directed theranostic concept.

However, due to the sensitivity of the pentixafor scaffold towards even small structural modifications such as radiometal exchange in the DOTA chelator (Poschenrieder et al. 2016b), different dedicated precursors are required for diagnostic and therapeutic applications. In this context, copper radionuclides represent an interesting imaging option. Although 64Cu (t1/2 = 12.7 h, β+ = 19%, Eβ + max = 656 keV, β- = 38%, Eβ-max = 578 keV) decays by both β+ and β- emission, its low β+ energy, which is comparable to that of 18F (Eβ + max = 633 keV), provides high spatial resolution in PET imaging (Williams et al. 2005) and its comparably long half-life is advantageous for performing kinetic PET imaging studies over extended periods of time.

To date, only a few 64Cu-labeled CXCR4-ligands have been reported. They are either based on the bicyclam AMD3100 (Weiss et al. 2012; De Silva et al. 2011; Nimmagadda et al. 2010; Jacobson et al. 2009) or chelator-conjugated T140 analogs (Jacobson et al. 2012; Jacobson et al. 2011). Despite promising in vitro CXCR4 targeting properties, the biodistribution of these compounds is invariably characterized by high non-specific accumulation and retention of 64Cu activity in the excretion organs (20-40% ID/g), especially in liver and kidneys, hinting -at least partly- towards a limited in vivo stability of the respective 64Cu-complexes.

Thus, to be able to nevertheless exploit the favorable radionuclide characteristics of 64Cu, this study was aimed at developing a 64Cu-labeled CXCR4-targeted probe, which combines high 64Cu-complex stability with the favorable in vivo pharmacokinetics of pentixafor-based ligands. Thermodynamically stable (Bevilacqua et al. 1987; Wu et al. 2016; Jones-Wilson et al. 1998) and, depending on the conjugated biomolecule, kinetically inert (Zarschler et al. 2014; Dearling et al. 2011) 64Cu complexes are formed with a variety of chelators (Cai & Anderson 2014; Wadas et al. 2007), including NOTA.

As first demonstrated for [177Lu]pentixather, the pentixather scaffold is substantially less sensitive towards structural modifications than pentixafor (Schottelius et al. 2015; Herrmann et al. 2016). Since NOTA forms stable Cu2+-complexes and a NOTA-for-DOTA exchange retained the favorable CXCR4-targeting properties of pentixather conjugates (Poschenrieder et al. 2016a), we were interested in the corresponding 64Cu-conjugates for PET imaging of CXCR4 expression in vivo. The possibility to further extend this tracer concept towards radiolabeling with copper radionuclides was now exemplarily evaluated by the detailed in vitro and in vivo investigation of 64Cu-labeled NOTA- and NODAGA-analogs of pentixather (Fig. 1).
Fig. 1

Chemical structures of [Cu]NOTA and [Cu]NODAGA-pentixather

Results

Radiolabeling

Under standard labeling conditions, [64Cu]NOTA-pentixather was obtained in radiochemical yields ≥90%. Radiochemical purities after C8-light purification were >99%, as confirmed by radio-TLC. The specific activity was 43 GBq/μmol.

Determination of the lipophilicity (logP)

[64Cu]NOTA-pentixather shows a logP of -1.2. Compared to its close structural analog [18F]AlF-NOTA-pentixather (log P = -1.4, (Poschenrieder et al. 2016a)), the 64Cu-labeled NOTA-peptide is slightly more lipophilic, whereas its lipophilicity is increased by more than an order of magnitude compared to [68Ga]pentixafor (log P = -2.90 (Gourni et al. 2011)).

Determination of CXCR4 affinities (IC50)

The CXCR4 affinities of [natCu]NOTA- and [natCu]NODAGA-pentixather as well as of the corresponding metal free chelator-conjugated peptides were determined in a competitive binding assay using standard conditions (CXCR4-expressing Jurkat T-lymphocytes (4 × 105 cells per sample) and [125I]FC131 as the radioligand (Poschenrieder et al. 2016a; Wester et al. 2015; Schottelius et al. 2015; Poschenrieder et al. 2016b)) (Table 1). Data for [natGa]pentixafor and FC131 are included as a reference. As already observed for [natGa]pentixafor, metal complexation leads to enhanced CXCR4 affinity, both for [natCu]NOTA-pentixather and for [natCu]NODAGA-pentixather. Compared to [natGa]pentixafor, however, [natCu]NOTA-pentixather showed almost twofold higher CXCR4 affinity, while it is reduced by a factor of two in the case of [natCu]NODAGA-pentixather.
Table 1

Affinities (IC50) of different Cu2+-labeled pentixafor derivatives, [natCu]NOTA, [natCu]NODAGA-pentixather, and the corresponding metal-free precursors to human CXCR4. FC131 and [68Ga]pentixafor are included as reference compounds. Competitive binding studies were carried out using Jurkat T-cell leukemia cells (400.000 cells/sample) and [125I]FC131 as the radioligand

Compound

IC50 [nM]

FC131

9.9 ± 2.4a

[natGa]pentixafor (DOTA)

24.8 ± 2.5a

[natCu]DOTAGA-pentixafor

1165 ± 220a

[natCu]NOTA-pentixafor

46.1 ± 26a

[natCu]NODAGA-pentixafor

343 ± 10a

[natCu]DTPA-pentixafor

175 ± 66a

NOTA-pentixather

27.5 ± 2.1

[natCu]NOTA-pentixather

14.9 ± 2.1

NODAGA-pentixather

64.9 ± 6.5

[natCu]NODAGA-pentixather

47.5 ± 1.8

aref (Poschenrieder et al. 2016b)

Data are means ± SD from a minimum of three separate determinations

Cell uptake and efflux studies

Figure 2a shows the CXCR4-specific total cellular uptake and internalization of [64Cu]NOTA-pentixather into Chem-1 cells, stably transfected with hCXCR4. The preferential use of this adherent cell line for the internalization and externalization studies was based on our previous observation that the determination of cellular uptake kinetics in suspension cells (such as Jurkat or Daudi cells (Wester et al. 2015)) is oftentimes biased by the experimental conditions (repeated centrifugation and resuspension steps), challenging cell viability and thus leading to inconsistent and irreproducible results. This effect was not encountered using Chem-1 cells. As shown in Fig. 2a, the total cellular [64Cu]NOTA-pentixather activity increases steadily over time, reaching approximately 12 and 22% of the added activity after 15 and 120 min, respectively. Internalization reaches a maximum after 30 min (~10%) and decreases to ~ 5% after 120 min. An exemplary efflux study is shown in Fig. 2b and reveals that 28% of the initial cellular [64Cu]NOTA-pentixather activity are retained after 120 min of externalization.
Fig. 2

a Total cellular uptake and internalization and b efflux kinetics of [64Cu]NOTA-pentixather in Chem-1 cells stably transfected with hCXCR4; 150000 cells/well were incubated with [64Cu]NOTA-pentixather (1 nM) at 37 °C in medium (5% BSA). The total cellular activity was corrected for non-specific binding in the presence of 100 μM AMD3100. Data are means ± SD

Biodistribution studies

Biodistribution data of [64Cu]NOTA-pentixather at 1.5 h p.i. (n = 5, black bars) and 24 h p.i. (n = 6, grey bars) in Daudi-lymphoma-bearing SCID mice are summarized in Fig. 3. Given the fact that Jurkat cells, which are generally used for the determination of CXCR4 affinity, are not tumorigenic in mice and to ensure comparability of data with previous studies (Poschenrieder et al. 2016a; Wester et al. 2015; Schottelius et al. 2015), the Daudi lymphoma model was also used in this study. Blood clearance of [64Cu]NOTA-pentixather was fast (1.1 ± 0.2% ID/g at 1.5 h p.i.), and activity accumulation in non-target organs was generally low. Due to the enhanced lipophilicity of [64Cu]NOTA-pentixather compared to [68Ga]pentixafor (logP = -2.90 (Gourni et al. 2011)), a certain extent of hepatobiliary excretion and thus non-specific accumulation in the liver and intestines were observed (7.2 ± 1.1 and 5.0 ± 2.8% ID/g, respectively), while activity accumulation in the kidney was comparably low (3.8 ± 0.5% ID/g). Tumor uptake of [64Cu]NOTA-pentixather was significantly higher than tracer accumulation in all other organs (13.1 ± 1.5% ID/g), underlining its excellent CXCR4 targeting efficiency. Coinjection of 2 mg/kg AMD3100 (Fig. 3, white bars) resulted in a reduction of tumor uptake by 88% (1.5 h p.i.), demonstrating the high CXCR4-specificity of [64Cu]NOTA-pentixather accumulation in the lymphoma xenograft. The resulting tumor-to-organ ratios at 1.5 and 24 h p.i. are summarized in Fig. 4. While the tumor-to-background ratios for most tissues remain unchanged or decrease within the observation period, t/blood and t/intestine ratios increase 1.3 and 2.4 fold between 1.5 and 24 h p.i., respectively.
Fig. 3

Biodistribution of [64Cu]NOTA-pentixather at 1.5 h (tracer only, black bars, n = 5) and 24 h p.i. (grey bars, n = 6) in Daudi xenograft-bearing CB-17 SCID mice. Mice were injected with 5.2 MBq [64Cu]NOTA-pentixather (122 pmol/0.160 μg peptide; AS = 43 GBq/μmol). Non-specific tracer accumulation was determined by coinjection of 2 mg/kg AMD3100 (50 μg/mouse; white bars, n = 3)

Fig. 4

Tumor-to-organ ratios of [64Cu]NOTA-pentixather 1.5 and 24 h p.i. (black and grey bars, respectively)

Small animal PET imaging

Representative PET/CT images of [64Cu]NOTA-pentixather in Daudi-lymphoma bearing SCID mice at 1 h, 3.5 h, and 24 h p.i. are shown in Fig. 5. Besides high and CXCR4-specific uptake of [64Cu]NOTA-pentixather in the Daudi lymphoma xenograft, some background activity uptake is observed in the liver, the gall bladder, and the intestines. Upon coinjection with 50 μg AMD3100, tumor accumulation is reduced to background levels (Fig. 5b), demonstrating that tumor uptake of [64Cu]NOTA-pentixather is almost exclusively CXCR4-mediated.
Fig. 5

PET/CT imaging (maximal intensity projections (MIP)) of Daudi xenograft bearing CB-17 SCID mice at 1 h p.i. of 5.2 MBq [64Cu]NOTA-pentixather; (a) tracer only, (b) coinjection of 2 mg/kg AMD3100; (c) and (d) images at 3.5 and 24 h p.i. (tracer only)

Figure 6 shows time-activity-curves (TACs) obtained by [64Cu]NOTA-pentixather PET for the heart (blood pool), kidney, liver, muscle, and tumor and further illustrates the rapid and continuous accumulation of [64Cu]NOTA-pentixather in the Daudi xenograft, accompanied by rapid background clearance.
Fig. 6

Time-activity-curves of heart, kidney, liver, muscle, and tumor after injection of [64Cu]NOTA-pentixather into Daudi lymphoma-bearing SCID mice

Metabolite analysis and EDTA challenge

To investigate the in vitro stability of [64Cu]NOTA-pentixather, the tracer was incubated both in human serum at 37 °C and in 0.1 M EDTA at pH = 2.5 and physiological pH (7.4) at RT for different time points up to 24 h (Fig. 7). [64Cu]NOTA-pentixather remained stable over 24 h in human serum (>99% intact 64Cu-chelate). Additionally, high resistance towards transchelation was demonstrated in challenge experiments with excess EDTA (0.1 M) (logKCu-EDTA = 18.7 (Jones-Wilson et al. 1998)), since over 90% of [64Cu]NOTA-pentixather were found to remain intact, even at pH 2.5 after 24 h.
Fig. 7

In vitro stability of [64Cu]NOTA-pentixather as a function of incubation time. [64Cu]NOTA-pentixather was incubated in human serum at 37 °C (■) or 0.1 M EDTA at different pH values (7.4: ▲, 2.5: ) at 25 °C

The in vivo stability of the tracer was investigated via metabolite studies in mice. Radio-HPLC analysis of urine and blood as well as tissue homogenates from liver and kidney showed that 98% intact [64Cu]NOTA-pentixather were present in blood and urine, while 68 and 24% intact tracer were found in liver and kidney, respectively.

Discussion

Excellent reviews on the multiple facets of copper chelation chemistry highlight the various aspects that need to be taken into account in the development of copper-radiopharmaceuticals with suitable in vivo biodistribution profiles (Cai & Anderson 2014; Wadas et al. 2007; Anderson & Ferdani 2009; Tegoni et al. 2014).

Despite reasonable thermodynamic stability, macrocyclic Cu2+ complexes, e.g. DOTA-complexes, are oftentimes prone to in vivo dissociation and transchelation due to challenge with e.g. endogenous metal ions or metal-binding proteins under very dilute tracer concentrations (Jones-Wilson et al. 1998; Kukis et al. 1994), leading to significant non-specific activity accumulation in the liver or other non-target tissues (Bass et al. 2000; Boswell et al. 2004) at least at later time points. Thus, copper complexes with high kinetic inertness, which are formed with specific macrocyclic nonbridged (e.g. cyclen and cyclam derivatives, including 1,4,8,11-tetraazacyclododecane-1,4,8,11-tetraacetic acid (TETA), NOTA or NODAGA), bridged macrocyclic chelators, (e.g. 1,8-ethylene cross-bridged cyclam derivatives like CB-TE2A), or sarcophagine-based chelators (e.g. diamSar) are primarily used for the preparation of copper radiopharmaceuticals (Cai & Anderson 2014; Wadas et al. 2007; Wadas et al. 2010).

Unfortunately, Cu2+-complexes of different pentixafor derivatives (Table 1) showed disappointing affinities towards CXCR4. However, due to structural modifications of the pentixafor scaffold, we found a conjugate, [Al18F2+]NOTA-pentixather, which demonstrated promising CXCR4-targeting properties in vitro and in vivo as well as suitable pharmacokinetics (Poschenrieder et al. 2016a). Thus, NOTA-pentixather as well as the corresponding NODAGA-analog were evaluated in this study as precursors for novel CXCR4-targeted 64Cu-radiopharmaceuticals. Because of the comparably low CXCR4 affinity of the [natCu]NODAGA conjugate (Table 1), only [natCu]NOTA-pentixather (Fig. 1) was selected for further preclinical evaluation.

Although [64Cu]NOTA chelates are generally of high stability (Zarschler et al. 2014; Dearling et al. 2011; Prasanphanich et al. 2007), dissociation of 64Cu has been reported to be influenced by the conjugated biomolecule, e.g. by exposed amino acid residues that compete with the chelator (Zarschler et al. 2014; Kukis et al. 1994; Boswell et al. 2004). Stability evaluation of [64Cu]NOTA-pentixather in vitro by means of serum incubation, acid-promoted dissociation studies, and EDTA-challenge experiments resulted in almost no transchelation when challenged and no albumin association. In vivo investigations demonstrated ≥98% intact 64Cu-chelate in urine and blood, whereas transchelation of 64Cu in kidney and liver occurred; Cu-dependent enzymes (e.g. superoxide dismutase (SOD)) or proteins (e.g. caeruloplasmin and metallothionein) are highly abundant in liver or kidney and are most probably responsible for inferior kinetic inertness of the tracer in these organs (Bass et al. 2000; McArdle et al. 1999; Terao & Owen 1973; Blower et al. 1996; Valentine et al. 1999; Musci et al. 1999). Transchelation of [64Cu]TETA-octreotide to SOD (Bass et al. 2000) and transfer of copper from a 67Cu-labeled antibody to ceruloplasmin (Mirick et al. 1999) were previously reported, accompanied by increasing blood activity levels, indicating the re-release of 64Cu from liver to the blood. However, this was not the case for [64Cu]NOTA-pentixather, which showed no dissociation in blood, both in vitro and in vivo, and displayed increasing tumor-to-blood ratios over time.

Moreover, activity accumulation in excretory organs 1.5 h p.i. was similar to that of [18F]AlF-NOTA-pentixather (logP = -1.4); hence, the shift towards hepatobiliary excretion and thus unspecific accumulation in the liver and intestines can be attributed to its slightly enhanced lipophilicity (logP = -1.2) rather than the instability of the 64Cu-chelate. Although NOTA causes a slightly enhanced lipophilicity compared to the parental compound [68Ga]pentixafor (logP = -2.9), NOTA offered suitable properties as chelator in novel pentixafor-based 64Cu-radiopharmaceuticals.

Although no transchelation or metabolization assays have been performed for the reported 64Cu-labeled T140 derivatives (T140-2D, DOTA-, and NOTA-T140-NFB), the authors suggest the formation of metabolites of the labeled peptides in vivo because, in contrast to [18F]T140, all of them shared high, long-lasting, and mostly unspecific uptake in liver and kidneys (Jacobson et al. 2012; Jacobson et al. 2011) which impairs their use as ideal PET imaging agent.

Besides the tetradecapeptides, two AMD-based CXCR4-targeting 64Cu-labeled tracers have been reported, namely [64Cu]AMD3100 and [64Cu]AMD3465 (Weiss et al. 2012; De Silva et al. 2011; Nimmagadda et al. 2010; Jacobson et al. 2009). The latter providing very high and specific tumor uptake; however both tracers also show high uptake in the liver and kidneys. In contrast to 64Cu-NOTA-pentixather and 64Cu-T140 derivatives, uptake in the liver was mostly specific; therefore, the authors suggest a CXCR4-independent component (Jacobson et al. 2009). Moreover, as tested by [64Cu]CuCl2 injected mice, transchelation did not contribute to the increased uptake in kidneys or liver. However, after 10 h, % ID/g values in the blood increased which hints towards transchelation at delayed time points (De Silva et al. 2011).

In the case of [64Cu]NOTA-pentixather, the overall high stability is also reflected by increasing tumor-to-blood ratios, which, accompanied with its promising CXCR4-targeting properties, resulted in high-contrast PET/CT images of lymphoma xenografts (Fig. 5). As shown in TACs, tumor uptake was higher than activity accumulation in all other tissues already at 17 min p.i., highlighting the efficient CXCR4-targeting and fast clearance of the tracer from non-target tissue with comparably low unspecific background accumulation at all time points (Fig. 6). However, at 1.5 and 3.5 h p.i, some background accumulation in the excretion organs was still visible. As discussed, this hepatic and intestinal activity uptake is most probably the result of a slightly delayed overall clearance due to the enhanced lipophilicity of the tracer compared to [68Ga]pentixafor. At 24 h p.i., tracer clearance from the body is almost complete, resulting in very low residual activity in liver and tumor. Modest internalization and fast externalization kinetics (Fig. 2) contribute to the fast clearance from tumor tissue. Although, its use for endoradiotherapeutic purposes is therefore limited, [64Cu]NOTA-pentixather proved as valuable PET agent for imaging of CXCR4 expression in vivo.

Conclusion

In summary we were able to successfully transfer our ‘pentixafor/pentixather’-based CXCR4-targeting technology to a promising analog for 64Cu-labeling. Due to the suitable in vitro and in vivo stability of the tracer, its rapid and specific activity accumulation in the Daudi xenograft, as well as rapid clearance from the background, PET images resulted in a clear delineation of the experimental tumors in vivo. However, fast clearance from the human xenografts and some uptake in the excretory organs, attributed to its slightly enhanced lipophilicity, limit the tracer’s efficiency for a further therapeutic transfer with 67Cu. The initial results recommend further investigations with [64Cu]NOTA-pentixather for CXCR4-PET imaging.

Methods

General procedures and syntheses of the peptides were performed as described (Poschenrieder et al. 2016b).

[natCu]NOTA-pentixather

The non-radioactive reference compound [natCu]NOTA-pentixather was prepared by mixing a 2 mM solution of NOTA-pentixather (250 μL) with an equal volume of 2 mM Cu(OAc)2 (pH = 6.0) and allowing the complexation reaction to proceed at room temperature (RT) for 30 min. Quantitative complex formation was confirmed by HPLC analysis.

HPLC (30 to 55%B in 15 min): tR = 12.3 min; calculated monoisotopic mass for [natCu]NOTA-pentixather (C56H70CuIN13O12): 1306.4; found (ESI-MS): m/z = 1307.7 [M + H]+.

[natCu]NODAGA-pentixather

The non-radioactive reference compound [natCu]NODAGA-pentixather was prepared as described above. Quantitative complex formation was confirmed by HPLC analysis.

HPLC (30 to 55%B in 15 min): tR = 12.3 min; calculated monoisotopic mass for [natCu]NOTA-pentixather (C59H74CuIN13O14): 1378.4; found (ESI-MS): m/z = 1379.8 [M + H]+.

64Cu-labeling of NOTA-pentixather

[64Cu]CuCl2 in 0.1 M HCl was obtained from the University of Tübingen. For peptide radiolabeling, 25 μL of [64Cu]CuCl2 (273 MBq) were added to an aqueous solution containing 150 μL 0.4 M NaOAc buffer (pH = 5.5) and 5 nmol of NOTA-pentixather. After heating to 60 °C for 10 min, the reaction mixture was allowed to cool to RT, and [64Cu]NOTA-pentixather was isolated via solid phase extraction using a C8-light cartridge (Waters). The product was eluted from the solid phase using a small volume of ethanol containing 0.5% (v/v) acetic acid.

EDTA-challenge

For challenging experiments, 4 MBq of [64Cu]NOTA-pentixather were incubated in 0.1 M EDTA at different pH values (2.5 and 7.4) for a minimum of 24 h. At specific time points, samples were analyzed via radio-TLC using silica gel impregnated chromatography paper (Agilent Technologies, CA, USA) and 0.1 M phosphate buffer (pH = 7.4) containing 10 mM sodium EDTA as the mobile phase.

Determination of lipophilicity and serum stability

The lipophilicity and serum stability of [64Cu]NOTA-pentixather were determined as described previously (Poschenrieder et al. 2016a). Briefly, to a solution of app. 2 kBq of radiolabelled peptide in 500 μL of PBS (pH 7.4), 500 μL of octanol were added (n = 6). Vials were vortexed vigorously for 3 min. To achieve quantitative phase separation, the vials were centrifuged at 14,600 · g for 6 min in a Biofuge 15 (Heraeus Sepatech, Osterode, Germany). The activity concentrations in 100 μL samples of both the aqueous and the organic phase were measured in a gamma counter, and the log Pow was calculated.

In vitro studies

CXCR4 affinities were determined using Jurkat T-cell leukemia cells and [125I]FC131 as the radioligand (Poschenrieder et al. 2016b). Briefly, cells (4 × 105 cells per vial) were incubated with app. 0.1 nM of [125I]FC131 in the presence of varying concentrations (10−11 to 10−5 M) of the respective peptide of interest (n = 3 samples/concentration) for 120 min at RT. After centrifugation and repeated washing steps, the amount of free and bound radioligand were quantified for each sample using a γ-counter, and IC50 values were calculated using GraphPad Prism 6.01 software.

Internalization and efflux studies were performed as described (Poschenrieder et al. 2016a) using Chem-1 cells stably transfected with hCXCR4 (HTS004C, Merck Millipore, Darmstadt, Germany). Briefly, adherent cells in 24-well plates (150,000/well) were incubated with 1 nM [64Cu]NOTA-pentixather in the absence (total binding) or presence of 100 μM AMD3100 (non-specific binding) at 37 °C for different time intervals up to 60 min. Subsequently, the amount of free, membrane-bound, and internalized activity were quantified for each sample using a γ-counter. For efflux studies, [64Cu]NOTA-pentixather was first allowed to internalize at 37 °C for 45 min. Then, the supernatant was exchanged by ligand-free assay medium, and efflux of [64Cu]NOTA-pentixather over time was investigated (37 °C). The remaining total cellular activity (membrane-bound + internalized activity) at different time points was quantified as described above.

In vivo studies

All animal studies were approved by the local authorities (No.: 55.2-1-54-2532-71-13) and are in compliance with the institution’s guidelines. For metabolite analysis, 18 MBq of [64Cu]NOTA-pentixather in a total volume of 200 μL of phosphate-buffered saline (PBS) were injected into the tail vein of a CB17 SCID mouse. At 1 h p.i., the animal was sacrificed and blood, urine, kidneys, and liver were collected. After sample preparation (Weineisen et al. 2014), the samples were analyzed by reversed phase (RP)-HPLC.

For PET and biodistribution studies, an average of 5.2 MBq [64Cu]NOTA-pentixather (200 μL in PBS, 122 pmol, 160 ng) with a SA of 43 GBq/μmol was injected intravenously into the tail vein of isofluorane anaesthesized female Daudi (human B-cell lymphoma) xenograft bearing CB17 SCID mice. CXCR4-specificity of [64Cu]NOTA-pentixather uptake was demonstrated by coinjection of 2 mg/kg AMD3100. PET imaging with [64Cu]NOTA-pentixather under ‘tracer only’ (n = 2) as well as blocking conditions (coinjection of 2 mg/kg AMD3100, n = 1) was performed at three different time points (dynamic PET imaging for 1 h, followed by static image acquisition for 15 min after 3.5 and 24 h) using an Inveon Siemens μPET scanner. PET/CT images were reconstructed by a two-dimensional ordered subset expectation maximum (2D-OSEM) algorithm with no attenuation correction. Image analysis was performed using the Inveon software, and results were calculated as %ID/g. For biodistribution studies, the mice were sacrificed at 1.5 h (n = 5) and 24 h (n = 6) p.i., tissues and organs of interest were dissected, weighed, and counted for radioactivity in a γ-counter. The percentage of injected dose per gram of tissue (% ID/g) was calculated; data are presented as mean ± SD.

Abbreviations

AMB: 

Aminomethylbenzoyl

AS

Specific activity

CXCR4: 

Chemokine receptor 4

DOTA: 

1,4,7,10-tetra azacyclododecane-1,4,7,10-tetraacetic acid

EDTA: 

Ethylenediaminetetraacetic acid

GRPR: 

Gastrin-releasing peptide receptor

IC50

Half maximal inhibitory concentration

MIP: 

Maximal intensity projection

NH4OAc: 

Ammonium acetate

NODAGA: 

1,4,7-triazacyclononane,1-glutaric acid-4,7-acetic acid

NOTA: 

1,4,7-triazacyclononane-triacetic acid

p.i.: 

Post injection

PBS: 

Phosphate-buffered saline

PET: 

Positron emission tomography

RP-HPLC: 

Reversed phase high-performance liquid chromatography

RT: 

Room temperature

SCID: 

Severe combined immunodeficiency

SOD: 

Superoxide dismutase

TAC: 

Time-activity curve

TETA: 

1,4,8,11-tetraazacyclododecane-1,4,8,11-tetraacetic acid

Declarations

Acknowledgements

This research project was funded by the Deutsche Forschungsgemeinschaft (DFG) (SFB 824, subprojects Z1 and B5) as well as by a TUM IGSSE grant (International Graduate School of Science and Engineering at TUM, BioMat03: CXCR4). The authors thank Christopher Kiwus for his assistance during the synthesis of the peptide conjugates. The authors are also indebted to Monika Beschorner, Sybille Reder, and Markus Mittelhäuser for their excellent technical assistance in the in vivo evaluation of [64Cu]NOTA-pentixather.

Authors’ contributions

AP planned and carried out the synthesis and evaluation of the compounds. MScho participated in the design of the study, contributed to data interpretation and revised the manuscript. TO contributed to syntheses and revised the manuscript. MS helped with coordination of the experiments and HJW helped analyzing and interpreting the data and initiated and designed the study. All authors approved the final manuscript.

Competing interests

Hans-Jürgen Wester is shareholder of Scintomics. All other authors declare to have no competing interests.

Ethics approval

All animal studies were conducted in accordance with the German Animal Welfare Act (Deutsches Tierschutzgesetz, approval no. 55.2-1-54-2532-71-13).

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Authors’ Affiliations

(1)
Pharmaceutical Radiochemistry, Technische Universität München
(2)
Department of Nuclear Medicine, Klinikum rechts der Isar, Technische Universität München

References

  1. Anderson CJ, Ferdani R. Copper-64 radiopharmaceuticals for PET imaging of cancer: advances in preclinical and clinical research. Cancer Biother Radiopharm. 2009;24(4):379–93. doi:10.1089/cbr.2009.0674.View ArticlePubMedPubMed CentralGoogle Scholar
  2. Bass LA, Wang M, Welch MJ, Anderson CJ. In vivo transchelation of copper-64 from TETA-octreotide to superoxide dismutase in rat liver. Bioconjug Chem. 2000;11(4):527–32.View ArticlePubMedGoogle Scholar
  3. Bevilacqua A, Gelb RI, Hebard WB, Zompa LJ. Equilibrium and thermodynamic study of the aqueous complexation of 1,4,7-triazacyclononane-N,N',N”-triacetic acid with protons, alkaline-earth-metal cations, and copper(Ii). Inorg Chem. 1987;26(16):2699–706. doi:10.1021/ic00263a029.View ArticleGoogle Scholar
  4. Blower PJ, Lewis JS, Zweit J. Copper radionuclides and radiopharmaceuticals in nuclear medicine. Nucl Med Biol. 1996;23(8):957–80.View ArticlePubMedGoogle Scholar
  5. Boswell CA, Sun X, Niu W, Weisman GR, Wong EH, Rheingold AL, et al. Comparative in vivo stability of copper-64-labeled cross-bridged and conventional tetraazamacrocyclic complexes. J Med Chem. 2004;47(6):1465–74. doi:10.1021/jm030383m.View ArticlePubMedGoogle Scholar
  6. Burger JA, Kipps TJ. CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. Blood. 2006;107. doi:10.1182/blood-2005-08-3182.
  7. Burger JA, Peled A. CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers. Leukemia. 2009;23(1):43–52. doi:10.1038/Leu.2008.299.View ArticlePubMedGoogle Scholar
  8. Cai Z, Anderson CJ. Chelators for copper radionuclides in positron emission tomography radiopharmaceuticals. J labelled compd radiopharm. 2014;57(4):224–30. doi:10.1002/jlcr.3165.View ArticleGoogle Scholar
  9. Chatterjee S, Azad BB, Nimmagadda S. The intricate role of CXCR4 in cancer. Adv Cancer Res. 2014;124:31–82. doi:10.1016/B978-0-12-411638-2.00002-1.View ArticlePubMedPubMed CentralGoogle Scholar
  10. De Silva RA, Peyre K, Pullambhatla M, Fox JJ, Pomper MG, Nimmagadda S. Imaging CXCR4 expression in human cancer xenografts: evaluation of monocyclam 64Cu-AMD3465. J Nucl Med. 2011;52(6):986–93. doi:10.2967/jnumed.110.085613.View ArticlePubMedPubMed CentralGoogle Scholar
  11. Dearling JLJ, Voss SD, Dunning P, Snay E, Fahey F, Smith SV, et al. Imaging cancer using PET — the effect of the bifunctional chelator on the biodistribution of a 64Cu-labeled antibody. Nucl Med Biol. 2011;38(1):29–38. https://www.ncbi.nlm.nih.gov/pubmed/21220127.View ArticlePubMedPubMed CentralGoogle Scholar
  12. Debnath B, Xu S, Grande F, Garofalo A, Neamati N. Small molecule inhibitors of CXCR4. Theranostics. 2013;3(1):47–75. doi:10.7150/thno.5376.View ArticlePubMedPubMed CentralGoogle Scholar
  13. Demmer O, Gourni E, Schumacher U, Kessler H, Wester HJ. PET imaging of CXCR4 receptors in cancer by a New optimized ligand. Chemmedchem. 2011a;6(10):1789–91. doi:10.1002/Cmdc.201100320.View ArticlePubMedPubMed CentralGoogle Scholar
  14. Demmer O, Dijkgraaf I, Schumacher U, Marinelli L, Cosconati S, Gourni E, et al. Design, synthesis, and functionalization of dimeric peptides targeting Chemokine receptor CXCR4. J Med Chem. 2011b;54(21):7648–62. doi:10.1021/Jm2009716.View ArticlePubMedGoogle Scholar
  15. Domanska UM, Kruizinga RC, Nagengast WB, Timmer-Bosscha H, Huls G, de Vries EGE, et al. A review on CXCR4/CXCL12 axis in oncology: No place to hide. Eur J Cancer. 2013;49(1):219–30. doi:10.1016/J.Ejca.2012.05.005.View ArticlePubMedGoogle Scholar
  16. George GP, Pisaneschi F, Nguyen QD, Aboagye EO. Positron emission tomographic imaging of CXCR4 in cancer: challenges and promises. Mol Imaging. 2014;13:1–19.Google Scholar
  17. Gourni E, Demmer O, Schottelius M, D’Alessandria C, Schulz S, Dijkgraaf I, et al. PET of CXCR4 expression by a (68)Ga-labeled highly specific targeted contrast agent. J Nucl Med. 2011;52(11):1803–10. doi:10.2967/jnumed.111.098798.View ArticlePubMedGoogle Scholar
  18. Hanaoka H, Mukai T, Tamamura H, Mori T, Ishino S, Ogawa K, et al. Development of a 111In-labeled peptide derivative targeting a chemokine receptor, CXCR4, for imaging tumors. Nucl Med Biol. 2006;33(4):489–94. doi:10.1016/j.nucmedbio.2006.01.006.View ArticlePubMedGoogle Scholar
  19. Hartimath SV, van Waarde A, Dierckx RA, de Vries EF. Evaluation of N-[(11)C]methyl-AMD3465 as a PET tracer for imaging of CXCR4 receptor expression in a C6 glioma tumor model. Mol Pharm. 2014;11(11):3810–7. doi:10.1021/mp500398r.View ArticlePubMedGoogle Scholar
  20. Hattermann K, Mentlein R. An infernal trio: the Chemokine CXCL12 and its receptors CXCR4 and CXCR7 in tumor biology. Annals of anatomy. Anat Anz. 2013;195(2):103–10. doi:10.1016/j.aanat.2012.10.013.View ArticleGoogle Scholar
  21. Herhaus P, Habringer S, Philipp-Abbrederis K, Vag T, Gerngross C, Schottelius M, et al. Targeted positron emission tomography imaging of CXCR4 expression in patients with acute myeloid leukemia. Haematologica. 2016;101(8):932–40. doi:10.3324/haematol.2016.142976.View ArticlePubMedPubMed CentralGoogle Scholar
  22. Herrmann K, Lapa C, Wester HJ, Schottelius M, Schiepers C, Eberlein U, et al. Biodistribution and radiation dosimetry for the chemokine receptor CXCR4-targeting probe 68Ga-pentixafor. J Nucl Med. 2015;56(3):410–6. doi:10.2967/jnumed.114.151647.View ArticlePubMedGoogle Scholar
  23. Herrmann K, Schottelius M, Lapa C, Osl T, Poschenrieder A, Hanscheid H, et al. First-in-human experience of CXCR4-directed endoradiotherapy with Lu-177- and Y-90-labeled pentixather in advanced-stage multiple myeloma with extensive intra- and extramedullary disease. J Nucl Med. 2016;57(2):248–51. doi:10.2967/jnumed.115.167361.View ArticlePubMedGoogle Scholar
  24. Jacobson O, Weiss ID, Szajek L, Farber JM, Kiesewetter DO. 64Cu-AMD3100--a novel imaging agent for targeting chemokine receptor CXCR4. Bioorg Med Chem. 2009;17(4):1486–93. doi:10.1016/j.bmc.2009.01.014.View ArticlePubMedPubMed CentralGoogle Scholar
  25. Jacobson O, Weiss ID, Kiesewetter DO, Farber JM, Chen XY. PET of tumor CXCR4 expression with 4-F-18-T140. J Nucl Med. 2010;51(11)):1796–804. doi:10.2967/jnumed.110.079418.View ArticlePubMedPubMed CentralGoogle Scholar
  26. Jacobson O, Weiss ID, Szajek LP, Niu G, Ma Y, Kiesewetter DO, et al. PET imaging of CXCR4 using copper-64 labeled peptide antagonist. Theranostics. 2011;1:251–62.View ArticlePubMedPubMed CentralGoogle Scholar
  27. Jacobson O, Weiss ID, Szajek LP, Niu G, Ma Y, Kiesewetter DO, et al. Improvement of CXCR4 tracer specificity for PET imaging. J Control Release. 2012;157(2):216–23. doi:10.1016/j.jconrel.2011.09.076.View ArticlePubMedGoogle Scholar
  28. Jones-Wilson TM, Deal KA, Anderson CJ, McCarthy DW, Kovacs Z, Motekaitis RJ, et al. The in vivo behavior of copper-64-labeled azamacrocyclic complexes. Nucl Med Biol. 1998;25((6):523–30. https://www.ncbi.nlm.nih.gov/pubmed/9751418.View ArticlePubMedGoogle Scholar
  29. Kuil J, Buckle T, van Leeuwen FWB. Imaging agents for the chemokine receptor 4 (CXCR4). Chem Soc Rev. 2012a;41(15):5239–61. doi:10.1039/C2cs35085h.View ArticlePubMedGoogle Scholar
  30. Kuil J, Buckle T, van Leeuwen FW. Imaging agents for the chemokine receptor 4 (CXCR4). Chem Soc Rev. 2012b;41(15):5239–61. doi:10.1039/c2cs35085h.View ArticlePubMedGoogle Scholar
  31. Kukis DL, Diril H, Greiner DP, Denardo SJ, Denardo GL, Salako QA, et al. A comparative study of copper-67 radiolabeling and kinetic stabilities of antibody-macrocycle chelate conjugates. Cancer. 1994;73(S3):779–86. doi:10.1002/1097-0142(19940201)73:3+<779::AID-CNCR2820731306>3.0.CO;2-3.View ArticlePubMedGoogle Scholar
  32. Lapa C, Lückerath K, Kleinlein I, Monoranu CM, Linsenmann T, Kessler AF, et al. 68Ga-pentixafor-PET/CT for imaging of Chemokine receptor 4 expression in glioblastoma. Theranostics. 2016a;6((3):428–34. doi:10.7150/thno.13986.View ArticleGoogle Scholar
  33. Lapa C, Luckerath K, Rudelius M, Schmid JS, Schoene A, Schirbel A et al. [68Ga]Pentixafor-PET/CT for imaging of chemokine receptor 4 expression in small cell lung cancer - initial experience. Oncotarget. 2016. doi:10.18632/oncotarget.7063.
  34. McArdle HJ, Bingham MJ, Summer K, Ong TJ. Cu metabolism in the liver. In: Leone A, Mercer JFB, editors. Copper transport and its disorders: molecular and cellular aspects. Boston: Springer US; 1999. p. 29–37.View ArticleGoogle Scholar
  35. Mirick GR, O’Donnell RT, DeNardo SJ, Shen S, Meares CF, DeNardo GL. Transfer of copper from a chelated 67Cu-antibody conjugate to ceruloplasmin in lymphoma patients. Nucl Med Biol. 1999;26(7):841–5.View ArticlePubMedGoogle Scholar
  36. Musci G, Polticelli F, Calabrese L. Structure/function relationships in ceruloplasmin. In: Leone A, Mercer JFB, editors. Copper transport and its disorders: molecular and cellular aspects. Boston: Springer US; 1999. p. 175–82.View ArticleGoogle Scholar
  37. Nimmagadda S, Pullambhatla M, Stone K, Green G, Bhujwalla ZM, Pomper MG. Molecular imaging of CXCR4 receptor expression in human cancer xenografts with [64Cu]AMD3100 positron emission tomography. Cancer Res. 2010;70(10):3935–44. doi:10.1158/0008-5472.CAN-09-4396.View ArticlePubMedPubMed CentralGoogle Scholar
  38. Oltmanns D, Zitzmann-Kolbe S, Mueller A, Bauder-Wuest U, Schaefer M, Eder M, et al. Zn(II)-bis(cyclen) complexes and the imaging of apoptosis/necrosis. Bioconjug Chem. 2011;22(12):2611–24. doi:10.1021/bc200457b.View ArticlePubMedGoogle Scholar
  39. Philipp-Abbrederis K, Herrmann K, Knop S, Schottelius M, Eiber M, Luckerath K, et al. In vivo molecular imaging of chemokine receptor CXCR4 expression in patients with advanced multiple myeloma. EMBO mol med. 2015;7(4):477–87. doi:10.15252/emmm.201404698.View ArticlePubMedPubMed CentralGoogle Scholar
  40. Poschenrieder A, Osl T, Schottelius M, Hoffmann F, Wirtz M, Schwaiger M, et al. First 18F-labeled pentixafor-based imaging agent for PET imaging of CXCR4 expression in vivo. Tomogr. 2016a;2(2):85–93. doi:10.18383/j.tom.2016.00130.View ArticleGoogle Scholar
  41. Poschenrieder A, Schottelius M, Schwaiger M, Kessler H, Wester H-J. The influence of different metal-chelate conjugates of pentixafor on the CXCR4 affinity. EJNMMI Res. 2016b;6(1):1–8. doi:10.1186/s13550-016-0193-8.View ArticleGoogle Scholar
  42. Poty S, Gourni E, Desogere P, Boschetti F, Goze C, Maecke HR, et al. AMD3100: a versatile platform for CXCR4 targeting (68)Ga-based radiopharmaceuticals. Bioconjug Chem. 2016;27(3):752–61. doi:10.1021/acs.bioconjchem.5b00689.View ArticlePubMedGoogle Scholar
  43. Prasanphanich AF, Nanda PK, Rold TL, Ma L, Lewis MR, Garrison JC, et al. [64Cu-NOTA-8-Aoc-BBN(7-14)NH2] targeting vector for positron-emission tomography imaging of gastrin-releasing peptide receptor-expressing tissues. Proc Natl Acad Sci U S A. 2007;104(30):12462–7. doi:10.1073/pnas.0705347104.View ArticlePubMedPubMed CentralGoogle Scholar
  44. Schottelius M, Osl T, Poschenrieder A, Herrmann K, Lapa C, Hoffmann F, et al. [177]Lu-pentixather: preclinical and first patient results with a highly promising CXCR4-directed endoradiotherapeutic agent. J Nucl Med. 2015;56(supplement 3):339.Google Scholar
  45. Tamamura H, Xu Y, Hattori T, Zhang X, Arakaki R, Kanbara K, et al. A low-molecular-weight inhibitor against the chemokine receptor CXCR4: a strong anti-HIV peptide T140. Biochem Biophys Res Commun. 1998;253(3):877–82. doi:10.1006/bbrc.1998.9871.View ArticlePubMedGoogle Scholar
  46. Tamamura H, Hori A, Kanzaki N, Hiramatsu K, Mizumoto M, Nakashima H, et al. T140 analogs as CXCR4 antagonists identified as anti-metastatic agents in the treatment of breast cancer. FEBS Lett. 2003;550(1-3):79–83.View ArticlePubMedGoogle Scholar
  47. Tanaka T, Nomura W, Narumi T, Masuda A, Tamamura H. Bivalent ligands of CXCR4 with rigid linkers for elucidation of the dimerization state in cells. J Am Chem Soc. 2010;132(45):15899–901. doi:10.1021/ja107447w.View ArticlePubMedGoogle Scholar
  48. Tegoni M, Valensin D, Toso L, Remelli M. Copper chelators: chemical properties and bio-medical applications. Curr Med Chem. 2014;21(33):3785–818.View ArticlePubMedGoogle Scholar
  49. Terao T, Owen CA. Nature of copper compounds in liver supernate and bile of rats: studies with 67 Cu. Am J Physiol. 1973;224(3):682–6. Legacy Content.PubMedGoogle Scholar
  50. Vag T, Gerngross C, Herhaus P, Eiber M, Philipp-Abbrederis K, Graner FP et al. First Experience on Chemokine Receptor CXCR4 Targeted Positron Emission Tomography (PET) Imaging in Patients with Solid Cancers. J Nucl Med. 2016. doi:10.2967/jnumed.115.161034.
  51. Valentine JS, Hart PJ, Gralla EB. Copper-zinc superoxide dismutase and ALS. In: Leone A, Mercer JFB, editors. Copper transport and its disorders: molecular and cellular aspects. Boston: Springer US; 1999. p. 193–203.View ArticleGoogle Scholar
  52. Wadas TJ, Wong EH, Weisman GR, Anderson CJ. Copper chelation chemistry and its role in copper radiopharmaceuticals. Curr Pharm Des. 2007;13(1):3–16.View ArticlePubMedGoogle Scholar
  53. Wadas TJ, Wong EH, Weisman GR, Anderson CJ. Coordinating radiometals of copper, gallium, indium, yttrium, and zirconium for PET and SPECT imaging of disease. Chem Rev. 2010;110(5):2858–902. doi:10.1021/Cr900325h.View ArticlePubMedPubMed CentralGoogle Scholar
  54. Weineisen M, Simecek J, Schottelius M, Schwaiger M, Wester HJ. Synthesis and preclinical evaluation of DOTAGAconjugated PSMA ligands for functional imaging and endoradiotherapy of prostate cancer. EJNMMI Res. 2014;4(63):1–15.Google Scholar
  55. Weiss ID, Jacobson O. Molecular imaging of chemokine receptor CXCR4. Theranostics. 2013;3(1):76–84. doi:10.7150/thno.4835.View ArticlePubMedPubMed CentralGoogle Scholar
  56. Weiss ID, Jacobson O, Kiesewetter DO, Jacobus JP, Szajek LP, Chen X, et al. Positron emission tomography imaging of tumors expressing the human chemokine receptor CXCR4 in mice with the use of 64Cu-AMD3100. Mol Imaging Biol. 2012;14(1):106–14. doi:10.1007/s11307-010-0466-y.View ArticlePubMedGoogle Scholar
  57. Wester HJ, Keller U, Schottelius M, Beer A, Philipp-Abbrederis K, Hoffmann F, et al. Disclosing the CXCR4 expression in lymphoproliferative diseases by targeted molecular imaging. Theranostics. 2015;5(6):618–30. doi:10.7150/thno.11251.View ArticlePubMedPubMed CentralGoogle Scholar
  58. Williams HA, Robinson S, Julyan P, Zweit J, Hastings D. A comparison of PET imaging characteristics of various copper radioisotopes. Eur J Nucl Med Mol I. 2005;32(12):1473–80. doi:10.1007/s00259-005-1906-9.View ArticleGoogle Scholar
  59. Woodard LE, De Silva RA, Behnam Azad B, Lisok A, Pullambhatla M, GL W, et al. Bridged cyclams as imaging agents for chemokine receptor 4 (CXCR4). Nucl Med Biol. 2014;41(7):552–61. doi:10.1016/j.nucmedbio.2014.04.081.View ArticlePubMedPubMed CentralGoogle Scholar
  60. Wu N, Kang CS, Sin I, Ren S, Liu D, Ruthengael VC, et al. Promising bifunctional chelators for copper 64-PET imaging: practical (64)Cu radiolabeling and high in vitro and in vivo complex stability. J biol inorg chem. 2016;21(2):177–84. doi:10.1007/s00775-015-1318-7.View ArticlePubMedGoogle Scholar
  61. Yan X, Niu G, Wang Z, Yang X, Kiesewetter DO, Jacobson O et al. Al[F]NOTA-T140 Peptide for Noninvasive Visualization of CXCR4 Expression. Mol Imaging Biol. 2015. doi:10.1007/s11307-015-0872-2.
  62. Zarschler K, Kubeil M, Stephan H. Establishment of two complementary in vitro assays for radiocopper complexes achieving reliable and comparable evaluation of in vivo stability. RSC Adv. 2014;4(20):10157–64. doi:10.1039/c3ra47302c.View ArticleGoogle Scholar

Copyright

© The Author(s) 2017